| Literature DB >> 27904531 |
Gündüz Yümün1, Cüneyt Kahaman2, Nail Kahaman3, Ulviye Yalçınkaya4, Aydin Akçılar5, Engin Akgül6, Ahmet Hakan Vural6.
Abstract
INTRODUCTION: Hyperbaric oxygen and platelet-rich plasma are used in the treatment of diabetic wounds. The aim of this study is to evaluate the effects of hyperbaric oxygen therapy and autologous platelet concentrates in healing diabetic wounds.Entities:
Keywords: combination therapy; hyperbaric oxygen; platelet-rich plasma
Year: 2016 PMID: 27904531 PMCID: PMC5108389 DOI: 10.5114/aoms.2016.62905
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
Figure 1 A–CCreation and closing of the wound
Figure 2Angiogenesis is indicated by the blue color (CD34). Group microscopic images: A – control group, B – hyperbaric oxygen group, C – platelet-rich plasma group, D – combined group
Figure 3The wound excised with surrounding tissue and photographed for area measurement
Rats’ characteristics before and after the trial
| Paramter | Control | PRP | HBO | Combined | Total | |
|---|---|---|---|---|---|---|
| Before the trial: | ||||||
| Blood glucose [mg/dl] | 92 ±9 | 107 ±9 | 98 ±6 | 105 ±15 | 99 ±11 | 0.292 |
| Body weight [g] | 242 ±9 | 222 ±9 | 228 ±13 | 228 ±7 | 228 ±13 | 0.111 |
| After the trial: | ||||||
| Blood glucose [mg/dl] | 299 (260–387) | 286 (251–360) | 356 (265–506) | 305 (254–357) | 302 (251–506) | 0.128 |
| Body weight [g] | 232 ±9 | 220 ±6 | 226 ±12 | 222 ±9 | 224 ±12 | 0.222 |
| Hemoglobin [g/dl] | 13.8 (13.3–14.3) | 13.5 (12.2–15.2) | 13.9 (13.4–14.6) | 13.7 (13.4–14.6) | 13.7 (12.2–15.2) | 0.489 |
| RDW (%) | 12.2 (11.9–13.1) | 11.2 (10.5–11.9) | 11.6 (11.2–12.2) | 11.5 (11.2–12) | 11.5 (10.5–13.1) | 0.001 |
| Platelets [× 103/µl] | 1062 (788–1694) | 669 (244–839) | 769 (691–879) | 810 (573–941) | 811 (244–1694) | 0.011 |
| Leukocytes [× 103/µl] | 2.9 ±1.1 | 4.7 ±2.8 | 3.2 ±1.7 | 3.1 ±2.4 | 3.5 ±2.1 | 0.506 |
| Lymphocytes [× 103/µl] | 2.28 (1.15–290) | 4.66 (0.14–7.6) | 2.38 (0.52–4.30) | 2.61 (0.52–6.71) | 2.61 (0.14–7.6) | 0.086 |
| Neutrophils [× 103/µl] | 0.1 (0.04–0.3) | 0.18 (0.03–0.2) | 0.5 (0.01–1) | 0.16 (0.06–0.24) | 0.25 (0.03–1) | 0.005 |
| Wound area [mm2] | 83.3 ±42.2 | 29.1 ±9.9 | 42.1 ±14.9 | 17.6 ±7.5 | 43.1 (11–130) | > 0.001 |
PRP – platelet-rich plasma group, HBO – hyperbaric oxygen group, Combined – combined platelet-rich plasma and hyperbaric oxygen group, Control – diabetic control group, RDW – red blood cell distribution width.
Histologic results according to treatment groups
| Parameter | Class | Control | PRP | HBO | Combined | Total | |
|---|---|---|---|---|---|---|---|
| Active skin ulcer | Yes | 5 (62.2%) | 2 (25%) | 3 (37.5%) | 1 (12.5%) | 10 (31.2%) | 0.184 |
| No | 3 (37.5%) | 7 (87.5%) | 5 (62.2%) | 7 (87.5%) | 22 (68.7%) | ||
| Epidermal thickening | Thin | 5 (62.2%) | 1 (12.5%) | 3 | 1 (12.5%) | 10 (31.2%) | 0.210 |
| Normal | – | 1 (12.5%) | 2 (25%) | 1 (12.5%) | 4 (12.5%) | ||
| Thick | 3 (37.5%) | 6 (75%) | 3 (37.5%) | 6 (75%) | 18 (56.2%) | ||
| Dermal vessel | Normal | 1 (12.5%) | 1 (12.5%) | – | 1 (12.5%) | 3 (9.3%) | 0.065 |
| Mildly increase | 4 (50%) | – | 2 (25%) | 2 (25%) | 8 (25%) | ||
| Moderate increase | 3 (37.5%) | 3 (37.5%) | 2 (25%) | 4 (50%) | 12 (37.5%) | ||
| Severe increase | – | 4 (50%) | 4 (50%) | 1 (12.5%) | 9 (28.1%) | ||
| Dermal collagen | Decrease | 7 (87.5%) | 1 (12.5%) | 3 (37.5%) | 1 (12.5%) | 12 (37.5%) | 0.008 |
| Normal | – | 1 (12.5%) | 2 (25%) | – | 3 (9.3%) | ||
| Increase | 1 (12.5%) | 6 (75%) | 3 (37.5%) | 7 (87.5%) | 17 (53%) | ||
| Foreign body reaction | Yes | 2 (25%) | 2 (25%) | 0 | 3 (37.5%) | 7 (21.8%) | 0.254 |
| No | 6 (75%) | 6 (75%) | 8 (100%) | 5 (62.2%) | 25 (78.1%) |
PRP – platelet-rich plasma group, HBO – hyperbaric oxygen group, Combined – combined platelet-rich plasma and hyperbaric oxygen group, Control – diabetic control group
statistically significant difference compared to control group.